What is the secondary attack rate for Nipah virus infection among close contacts?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Secondary Attack Rate for Nipah Virus Infection

The secondary attack rate for Nipah virus among close contacts ranges from approximately 50% in household settings, with person-to-person transmission documented in roughly half of all recognized cases in Bangladesh outbreaks. 1

Documented Transmission Patterns

Person-to-Person Transmission Frequency

  • Approximately 50% of recognized Nipah virus cases in Bangladesh developed their disease following person-to-person transmission, making human-to-human spread a major contributor to outbreak propagation 1
  • In the 2001 Meherpur outbreak, 7 of 13 cases (54%) occurred in persons from just two households, demonstrating intense household clustering 2
  • In the 2003 Naogaon outbreak, 7 of 12 cases (58%) were clustered in 2 households, again showing high secondary attack rates in close contact settings 2

Risk Factors for Secondary Transmission

  • Patients were significantly more likely to develop disease if they had close contact with other patients, establishing direct person-to-person contact as a primary risk factor 2
  • Exposure to infected patients' saliva represents a critical transmission route that family members and caregivers must avoid 1
  • Human transmission occurs through close contact with infected individuals, particularly in healthcare and household settings 3

Clinical Context and Outbreak Characteristics

Disease Severity and Mortality

  • The case fatality rate ranges from 40% to 75%, making prevention of secondary transmission critically important for outbreak control 4, 3
  • Clinical manifestations range from mild respiratory illness to severe and fatal encephalitis, with the severity influenced by healthcare availability, patient condition, and viral strain virulence 3

Geographic Distribution

  • Eight outbreaks have been reported from Bangladesh since 2001, with recurring patterns of household clustering 1
  • The virus has been documented in Malaysia, Bangladesh, and India, with fruit bats (genus Pteropus) serving as natural reservoirs 3

Prevention Strategies

Primary Prevention Measures

  • Decreasing bat access to date palm sap prevents primary transmission from the reservoir host 1
  • Reducing family members' and friends' exposure to infected patients' saliva is essential for preventing secondary cases 1

Surveillance Recommendations

  • Enhanced surveillance and diagnostic capacity to detect Nipah virus infection are recommended following any suspected outbreak 2
  • Early detection and prompt response are crucial for controlling outbreaks, though diagnostic challenges and delayed recognition remain significant barriers 3

Healthcare Worker Protection

  • Hospital workers in the investigated outbreaks tested negative for Nipah virus antibodies, suggesting that appropriate infection control measures can prevent nosocomial transmission 2

Important Caveats

The high secondary attack rate in household settings (approximately 50%) contrasts sharply with other infectious diseases and demands aggressive isolation and contact precaution measures. Unlike the meningococcal disease secondary attack rate of 4 per 1,000 household contacts 5, Nipah virus demonstrates far more efficient person-to-person transmission in close contact settings. The clustering of cases within households and the documented transmission through saliva exposure underscore the need for strict respiratory and contact precautions when managing suspected or confirmed cases.

References

Research

Transmission of human infection with Nipah virus.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009

Research

Nipah virus encephalitis reemergence, Bangladesh.

Emerging infectious diseases, 2004

Research

Nipah Virus: An Updated Review and Emerging Challenges.

Infectious disorders drug targets, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the recommended treatment for a patient suspected of being infected with the Nipah virus?
What is the prognosis and treatment for a patient suspected of having Nipah virus infection?
What is the latest information on Nipa virus infection management and treatment in patients with recent travel history to outbreak areas or potential contact with infected animals?
What is the recommended treatment and management approach for a patient suspected of having Nipah virus infection, presenting with respiratory and neurological symptoms?
What are the management recommendations for a patient with a pacemaker (permanent artificial cardiac pacemaker) who is at risk of or has been infected with Nipah virus?
How does alcohol abuse contribute to the development of necrotizing fasciitis in adults with compromised immune function?
Is neurosteroid downregulation a concern in a patient with hypotestosteronemia (low testosterone levels), brain fog, anxiety, and anhedonia, who is being treated with testosterone replacement therapy (TRT)?
What is the recommended oral suspension dose of amoxicillin for a child diagnosed with strep throat?
How is low serum albumin managed in patients with underlying conditions such as liver disease, nephrotic syndrome, or malnutrition?
Is antibiotic treatment needed for a patient, particularly high-risk individuals such as young children, immunocompromised individuals, or those with a history of severe infections, with varicella (chickenpox) blisters that have developed purulent discharge, and if so, what antibiotic should be given?
What is the recommended approach to managing hypogonadism in a male patient in his 50s or 60s with a decline in testosterone levels from 495 ng/dl to 288 ng/dl over 6 years, presenting with symptoms such as brain fog, anxiety, and anhedonia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.